Malignancy following treatment of rheumatoid arthritis with cyclophosphamide. Long-term case-control follow-up study

The American Journal of Medicine

Volumn 83, Issue 1, 1987, Pages 1-9

  Baker, Gary L ^a   Kahl, Leslie E ^a   Zee, Benny C ^a   Stolzer, Bertrand L ^a   Agarwal, Amrit K ^a   Medsger Jr , Thomas A ^a  

^a St Margaret Memorial Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; TOBACCO;

ADULT; BLADDER CANCER; ETIOLOGY; FEMALE; HEMATOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; RHEUMATOID ARTHRITIS; SKIN CANCER; SURVIVAL TIME;

ARTHRITIS, RHEUMATOID; COMPARATIVE STUDY; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMAN; MALE; MIDDLE AGE; NEOPLASMS; RETROSPECTIVE STUDIES; RISK; SUPPORT, NON-U.S. GOV'T; TIME FACTORS;

EID: 0023625490     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/0002-9343(87)90490-6     Document Type: Article

References (43)

1. Treatment of rheumatoid arthritis with nitrogen mustard preliminary report
2. Long-term cyclophosphamide therapy in rheumatoid arthritis
3. Controlled trial of cyclophosphamide in rheumatoid arthritis
4. Double-blind study of cyclophosphamide in rheumatoid arthritis
5. Comparison of high- and low-dose cyclophosphamide therapy in rheumatoid arthritis
6. Does drug therapy slow radiographic deterioration in rheumatoid arthritis?
7. Collaborative United Kingdom-Australasian study of cancer in patients treated with immunosuppressive drugs
8. Immunosuppression and cancer
9. Toxicity of antineoplastic agents
10. Second malignant neoplasms associated with immunosuppressive medication
11. Neoplasia and cyclophosphamide
12. Carcinoma of the urinary bladder in patients receiving cyclophosphamide
13. The causes of death in patients with rheumatoid arthritis treated with cytotoxic agents
14. Acute leukemia and immunosuppressive drug use
15. Cyclophosphamide and malignancy
16. Incidence of malignant disease in patients receiving cytotoxic therapy for rheumatoid arthritis
17. Incidence of malignancy 10 years following cyclophosphamide use for rheumatoid arthritis
18. The occurrence of malignancies in patients with rheumatoid arthritis treated with cyclophosphamide a controlled retrospective follow-up
19. 1958 revision of diagnostic criteria for rheumatoid arthritis
20. Malignant lymphomas in transplantation patients
21. Immunosurveillance and cancer: epidemiologic evidence
22. Review of United States-data on neoplasms in rheumatoid arthritis
23. Cyclophosphamide and the bladder
24. Transitional cell carcinoma of the bladder associated with cyclophosphamide
25. Cyclophosphamide
26. Urinary bladder tumors after cyclophosphamide
27. Bladder malignancy in a patient receiving a low dose cyclophosphamide for treatment of rheumatoid arthritis
28. Cyclophosphamide cystitis and bladder cancer: a hypothesis
29. The incidence of bladder cancer after cyclophosphamide therapy
30. Bladder complications in patients receiving cyclophosphamide for systemic lupus erythematosus or rheumatoid arthritis
31. Heavy phenacetin use and bladder cancer in women aged 20 to 49 years
32. Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphoma
33. Excess risk of lymphoma leukemia and myeloma in patients with rheumatoid arthritis
34. Cancer morbidity in rheumatoid arthritis
35. Acute leukemia in rheumatoid arthritis treated with cytotoxic agents
36. Chromosome abnormalities from cyclophosphamide therapy in rheumatoid arthritis and progressive systemic sclerosis
37. Cyclosporin A in immunosuppression, Epstein-Barr antibody, and lymphoma
38. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporine steroid therapy
39. Defective EBV-specific suppressor T-cell function in rheumatoid arthritis
40. Sjogren's syndrome. 2. Clinical associations and immunological phenomena
41. Occurrence of malignant neoplasms in the Rochester, Minnesota, rheumatoid arthritis cohort
42. Malignant melanoma in renal transplant recipients
43. Cutaneous malignant melanoma after Hodgkin's disease